GlassScriptPhysician profile
Selva Sunil Samuel
NPI 1790476125
$4,593.01
in general payments reported to CMS, 2019-2025
52 companies · $3,492 in 2025
The $3,492 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $328 · 2024: $773 · 2025: $3,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,247 · Education: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,246.63 |
| Education | $346.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $543.05 | 2023-2025 | Lokelma, Calquence, Farxiga |
| Janssen Biotech, INC. | $307.60 | 2025 | Talvey, Carvykti, Erleada |
| Novartis Pharmaceuticals Corporation | $249.74 | 2025 | |
| Daiichi Sankyo INC. | $209.48 | 2025 | Enhertu, Injectafer, Datroway |
| Sobi, INC | $188.44 | 2025 | |
| Ardelyx, INC. | $173.81 | 2024 | Xphozah 30 Mg, Ibsrela |
| Incyte Corporation | $170.92 | 2025 | Monjuvi, Jakafi, Zynyz |
| Amgen INC. | $156.28 | 2023-2024 | Repatha, Tavneos, Aranesp |
| E.R. Squibb & Sons, L.L.C. | $144.78 | 2024-2025 | Opdivo |
| Pfizer INC. | $140.39 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.36 | 2023-2025 | |
| Travere Therapeutics, INC. | $121.95 | 2024 | |
| Novo Nordisk INC | $119.70 | 2025 | Ozempic |
| Abbvie INC. | $107.67 | 2025 | |
| Celgene Corporation | $105.31 | 2025 | Reblozyl |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selva Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.